Lucid Diagnostics (NASDAQ:LUCD) Price Target Raised to $7.75

Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) had its price objective boosted by equities research analysts at Ascendiant Capital Markets from $7.50 to $7.75 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a "buy" rating on the stock.

Several other equities research analysts also recently weighed in on LUCD. BTIG Research set a $2.00 price objective on Lucid Diagnostics in a report on Tuesday, March 25th. Wall Street Zen lowered Lucid Diagnostics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Needham & Company LLC reaffirmed a "buy" rating and issued a $3.00 price objective on shares of Lucid Diagnostics in a research report on Wednesday, May 14th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $2.00 price objective on shares of Lucid Diagnostics in a research note on Thursday, May 15th. One research analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $3.55.

Lucid Diagnostics Stock Performance

NASDAQ LUCD traded up $0.08 during trading on Friday, reaching $1.29. 1,369,013 shares of the company's stock were exchanged, compared to its average volume of 570,360. The company has a 50 day moving average price of $1.33 and a two-hundred day moving average price of $1.17. The stock has a market cap of $139.56 million, a P/E ratio of -1.13 and a beta of 1.31. Lucid Diagnostics has a 1 year low of $0.68 and a 1 year high of $1.80.

Hedge Funds Weigh In On Lucid Diagnostics

Several institutional investors and hedge funds have recently made changes to their positions in LUCD. LPL Financial LLC lifted its holdings in Lucid Diagnostics by 29.1% during the 4th quarter. LPL Financial LLC now owns 53,391 shares of the company's stock worth $44,000 after buying an additional 12,035 shares during the last quarter. Geode Capital Management LLC lifted its stake in Lucid Diagnostics by 30.9% during the fourth quarter. Geode Capital Management LLC now owns 279,504 shares of the company's stock valued at $229,000 after purchasing an additional 65,964 shares during the last quarter. Lido Advisors LLC boosted its position in shares of Lucid Diagnostics by 40.0% in the 4th quarter. Lido Advisors LLC now owns 140,016 shares of the company's stock valued at $115,000 after purchasing an additional 40,000 shares during the period. Citadel Advisors LLC acquired a new position in shares of Lucid Diagnostics in the fourth quarter worth about $98,000. Finally, Sunbelt Securities Inc. acquired a new stake in shares of Lucid Diagnostics during the fourth quarter valued at approximately $67,000. 74.01% of the stock is currently owned by hedge funds and other institutional investors.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.